Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Eur J Cancer. 2021 Nov;157:474-484. doi: 10.1016/j.ejca.2021.08.036. Epub 2021 Oct 11.
Eur J Cancer. 2021.
PMID: 34649118
Free article.